Advertisement

Journal of Cancer Education

, Volume 33, Issue 2, pp 371–374 | Cite as

Quantitative Information on Oncology Prescription Drug Websites

  • Helen W. Sullivan
  • Kathryn J. Aikin
  • Linda B. Squiers
Article

Abstract

Our objective was to determine whether and how quantitative information about drug benefits and risks is presented to consumers and healthcare professionals on cancer-related prescription drug websites. We analyzed the content of 65 active cancer-related prescription drug websites. We assessed the inclusion and presentation of quantitative information for two audiences (consumers and healthcare professionals) and two types of information (drug benefits and risks). Websites were equally likely to present quantitative information for benefits (96.9 %) and risks (95.4 %). However, the amount of the information differed significantly: Both consumer-directed and healthcare-professional-directed webpages were more likely to have quantitative information for every benefit (consumer 38.5 %; healthcare professional 86.1 %) compared with every risk (consumer 3.1 %; healthcare professional 6.2 %). The numeric and graphic presentations also differed by audience and information type. Consumers have access to quantitative information about oncology drugs and, in particular, about the benefits of these drugs. Research has shown that using quantitative information to communicate treatment benefits and risks can increase patients’ and physicians’ understanding and can aid in treatment decision-making, although some numeric and graphic formats are more useful than others.

Keywords

Cancer Prescription drug Internet Marketing 

Notes

Acknowledgments

The study was funded by the Office of Prescription Drug Promotion, U.S. Food and Drug Administration. We would like to thank the following individuals who were compensated for their work: Susana Peinado, Ph.D. and Janice Tzeng, MPH, for their help in developing the coding scheme and coding the websites and Lisa Gilbert, Ph.D., for her contributions to designing the study.

References

  1. 1.
    Abel GA, Burstein HJ, Hevelone ND, Weeks JC (2009) Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol 27:4182–4187CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Viale PH, Yamamoto DS (2004) The attitudes and beliefs of oncology nurse practitioners regarding direct-to-consumer advertising of prescription medications. Oncol Nurs Forum 31:777–783CrossRefPubMedGoogle Scholar
  3. 3.
    Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Tamura K, Fujiwara Y (2012) Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. PLoS One 7(8):e44393CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gray SW, Abel GA (2012) Update on direct-to-consumer marketing in oncology. J Oncol Pract 8:124–127CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schwartz LM, Woloshin S (2013) The drug facts box: improving the communication of prescription drug information. Proc Natl Acad Sci 110(3):14069–14074CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Korenstein D, Keyhani S, Mendelson A, Ross JS (2011) Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One 6:e23336CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    West SL, Squiers LB, McCormack L, Southwell BG, Brouwer ES, Ashok M, Lux L, Boudewyns V, O’Donoghue A, Sullivan HW (2013) Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertising. Pharmacoepidemiol Drug Saf 22(5):447–458CrossRefPubMedGoogle Scholar
  8. 8.
    Sullivan HW, O’Donoghue AC, Aikin KJ (2015) Communicating benefit and risk information in direct-to-consumer print advertisements: a randomized study. Ther Innov Regul Sci 49:493–502CrossRefGoogle Scholar
  9. 9.
    Covey J (2007) A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Mak 27:638–654CrossRefGoogle Scholar
  10. 10.
    Lipkus I (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:697–713CrossRefGoogle Scholar
  11. 11.
    Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA (2014) Evidence-based risk communication: a systematic review. Ann Intern Med 161:270–280CrossRefPubMedGoogle Scholar
  12. 12.
    Abel GA, Lee SJ, Weeks JC (2007) Direct-to-consumer advertising in oncology: a content analysis of print media. J Clin Oncol 25(10):1267–1271CrossRefPubMedGoogle Scholar
  13. 13.
    Davis JJ (2012) Content analysis of efficacy descriptions on branded pharmaceutical websites. J Med Mark 12(4):211–220CrossRefGoogle Scholar
  14. 14.
    Woloshin S, Schwartz LM, Tremmel J, Gilbert Welch H (2001) Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 358(9288):1141–1146CrossRefPubMedGoogle Scholar
  15. 15.
    Kontos EZ, Viswanath K (2011) Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer 11(2):142–150CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  • Helen W. Sullivan
    • 1
  • Kathryn J. Aikin
    • 1
  • Linda B. Squiers
    • 2
  1. 1.U.S. Food and Drug AdministrationSilver SpringUSA
  2. 2.RTI InternationalResearch Triangle ParkUSA

Personalised recommendations